imp-2 Antibody

What is IGF2BP2/IMP-2 antibody and what biological systems does it recognize?

IGF2BP2/IMP-2 antibody is a tool used to detect the insulin-like growth factor 2 mRNA-binding protein 2, a critical RNA-binding factor that recruits target transcripts to cytoplasmic protein-RNA complexes (mRNPs). The most commonly used variant is a mouse monoclonal antibody that has been validated for reactivity with both human and mouse samples .

This antibody recognizes a protein that functions in transcript "caging" into mRNPs, which facilitates mRNA transport and transient storage. Additionally, IGF2BP2 modulates the rate and location at which target transcripts encounter the translational apparatus, while protecting them from endonuclease attacks or microRNA-mediated degradation. Of particular significance, IGF2BP2 preferentially binds to N6-methyladenosine (m6A)-containing mRNAs and enhances their stability .

How does the IMP-2 antibody differ from other antibodies targeting similar RNA-binding proteins?

The IGF2BP2/IMP-2 antibody is specifically designed to recognize the VICKZ family member 2 (VICKZ2), differentiating it from antibodies targeting other RNA-binding proteins within this family. What makes this antibody particularly valuable in research contexts is its specificity for a protein that demonstrates isoform-specific binding patterns .

Unlike antibodies targeting more general RNA-binding proteins, the IMP-2 antibody recognizes a protein with specific binding affinity for the 5'-UTR of insulin-like growth factor 2 (IGF2) mRNAs. It also recognizes a protein that binds to beta-actin/ACTB and MYC transcripts, with binding to MYC mRNA enhanced by m6A-modification of the coding region instability determinant (CRD) . This specificity makes it valuable for studying specialized RNA regulatory mechanisms that other antibodies cannot effectively target.

What are the recommended storage conditions and shelf-life considerations for IMP-2 antibody?

For optimal performance of IGF2BP2/IMP-2 antibody in research applications, proper storage is critical. Monoclonal antibodies like the IMP-2 antibody should generally be stored at -20°C for long-term preservation, while aliquots for more immediate use can be maintained at 4°C for shorter periods (typically 1-2 weeks).

To prevent degradation through freeze-thaw cycles, it is advisable to prepare small working aliquots before freezing. Most manufacturers recommend avoiding more than 5 freeze-thaw cycles to maintain antibody integrity and performance. The typical shelf-life for properly stored monoclonal antibodies ranges from 12-24 months, though this can vary based on formulation specifics and preservatives included. Researchers should verify the presence of expected bands at appropriate molecular weights in control samples before proceeding with critical experiments, particularly when using antibodies that have been stored for extended periods.

What are the validated applications for IGF2BP2/IMP-2 antibody in laboratory research?

The IGF2BP2/IMP-2 mouse monoclonal antibody has been validated for specific laboratory applications that researchers should consider when designing experiments. Based on available data, this antibody has been confirmed suitable for:

• Immunoprecipitation (IP): Enabling the isolation of IGF2BP2 and its associated RNA targets from complex cellular lysates.

• Western Blotting (WB): Allowing for the detection and semi-quantitative analysis of IGF2BP2 protein expression in cell and tissue lysates .

These applications have been specifically tested and validated with human and mouse samples, making the antibody particularly valuable for comparative studies across these species . While other potential applications exist for antibodies generally, researchers should either conduct validation studies for untested applications or select alternative antibodies that have been specifically validated for their application of interest.

How should researchers optimize western blotting protocols when using IMP-2 antibody?

When optimizing western blotting protocols with IGF2BP2/IMP-2 antibody, researchers should follow this methodological approach:

• Sample preparation: Extract proteins using RIPA or NP-40 buffer containing protease inhibitors. Determine protein concentration using Bradford or BCA assay to ensure equal loading.

• Gel electrophoresis: Use 8-10% SDS-PAGE gels as IGF2BP2 has a molecular weight of approximately 66 kDa.

• Transfer optimization: Employ wet transfer at 100V for 60-90 minutes or 30V overnight at 4°C to efficiently transfer high molecular weight proteins.

• Blocking: Use 5% non-fat dry milk or 3-5% BSA in TBST (Tris-buffered saline with 0.1% Tween-20) for 1 hour at room temperature.

• Primary antibody incubation: Dilute IGF2BP2/IMP-2 antibody to the manufacturer's recommended concentration (typically 1:500 to 1:2000) in blocking buffer. Incubate overnight at 4°C with gentle agitation.

• Washing: Perform 4-5 washes with TBST, 5-10 minutes each, to reduce background signal.

• Secondary antibody: Use species-appropriate HRP-conjugated secondary antibody (anti-mouse for monoclonal IGF2BP2 antibody) at 1:5000 to 1:10000 dilution for 1 hour at room temperature.

• Signal detection: Develop using ECL substrate and optimize exposure time to avoid signal saturation.

• Controls: Always include positive control samples (cell lines known to express IGF2BP2) and negative controls to validate specificity.

This methodological approach ensures reliable detection while minimizing background and non-specific binding that could compromise data interpretation.

What methodology should be followed for immunoprecipitation experiments using IMP-2 antibody?

For successful immunoprecipitation (IP) experiments using IGF2BP2/IMP-2 antibody, researchers should follow this structured methodological approach:

• Cell lysis: Harvest cells and lyse in a non-denaturing buffer (such as 20 mM Tris-HCl pH 8.0, 137 mM NaCl, 1% NP-40, 2 mM EDTA) supplemented with protease inhibitors. For RNA-immunoprecipitation (RIP) applications, include RNase inhibitors.

• Pre-clearing: Incubate lysate with protein A/G beads for 1 hour at 4°C to reduce non-specific binding.

• Antibody binding: Add 2-5 μg of IGF2BP2/IMP-2 antibody to 500-1000 μg of pre-cleared lysate. Incubate overnight at 4°C with gentle rotation.

• Immunoprecipitation: Add 50 μl of protein A/G magnetic or agarose beads, continue incubation for 2-4 hours at 4°C.

• Washing: Perform 4-5 stringent washes with lysis buffer to remove non-specifically bound proteins.

• Elution: For protein analysis, elute in SDS sample buffer by heating at 95°C for 5 minutes. For RNA analysis (in RIP experiments), use specialized RNA extraction methods.

• Analysis: Analyze immunoprecipitated material by western blotting to confirm successful IP of IGF2BP2, or proceed with RNA extraction and analysis for RIP experiments.

• Controls: Always include an IgG isotype control to identify non-specific binding and input samples (typically 5-10% of starting material) to assess IP efficiency.

This approach maximizes the likelihood of successful immunoprecipitation while maintaining the native protein-protein and protein-RNA interactions that are critical for studying IGF2BP2 function.

How can researchers evaluate and confirm the specificity of IMP-2 antibody in their experimental system?

Researchers can systematically evaluate and confirm IMP-2 antibody specificity through these methodological approaches:

• Knockout/knockdown validation: The gold standard for antibody validation involves comparing signal between wild-type samples and those where the target protein has been depleted using CRISPR-Cas9 knockout or siRNA/shRNA knockdown. A genuine antibody will show significantly reduced signal in depleted samples .

• Overexpression studies: Complementary to knockdown approaches, overexpressing tagged versions of IGF2BP2 should result in enhanced signal detection at the appropriate molecular weight.

• Peptide competition assay: Pre-incubating the antibody with an excess of the immunizing peptide should block specific binding sites and eliminate true target signals while leaving non-specific signals unchanged.

• Multiple antibody comparison: Using antibodies raised against different epitopes of IGF2BP2 should yield consistent results if each is specific.

• Positive and negative control tissues/cells: Test the antibody against samples known to express high levels of IGF2BP2 (positive controls) and those lacking expression (negative controls).

• Immunoprecipitation-mass spectrometry: IP followed by mass spectrometric analysis can verify that the precipitated protein is indeed IGF2BP2 and identify any cross-reactive proteins.

These methodological approaches provide complementary lines of evidence for antibody specificity, which is essential for generating reliable and reproducible research findings.

What potential cross-reactivity issues should researchers be aware of when using IMP-2 antibody?

Researchers using IGF2BP2/IMP-2 antibody should be attentive to several potential cross-reactivity issues that could compromise experimental interpretation:

• Homolog cross-reactivity: IGF2BP2 belongs to a family that includes the closely related IGF2BP1 and IGF2BP3 proteins, which share significant sequence homology. Antibodies targeting conserved epitopes may cross-react with these paralogs, particularly in applications like immunohistochemistry where protein conformation is altered .

• Isoform specificity: IGF2BP2 exists in multiple isoforms resulting from alternative splicing. Depending on the epitope recognized, an antibody may detect all isoforms or only specific variants, leading to inconsistent results when comparing to other detection methods .

• Species cross-reactivity: While the monoclonal IGF2BP2 antibody is reported to react with both human and mouse samples, cross-reactivity varies across species. Researchers working with other model organisms should perform validation studies before proceeding with full experiments .

• Non-specific binding in high-expression tissues: In tissues with abundant RNA-binding proteins, non-specific binding may occur, especially under suboptimal experimental conditions or inadequate blocking.

• Post-translational modification interference: Modifications such as phosphorylation or ubiquitination may alter epitope accessibility or antibody binding affinity, potentially resulting in misleading expression patterns.

To mitigate these issues, researchers should:

• Validate antibody specificity with appropriate controls

• Use complementary detection methods to confirm findings

• Optimize experimental conditions for each application and sample type

• Consider using multiple antibodies targeting different epitopes for critical experiments

How does epitope selection in antibody design influence the reliability of IMP-2 antibody for detecting different conformational states of the protein?

The epitope selection in antibody design significantly impacts the reliability of IGF2BP2/IMP-2 antibody for detecting various conformational states of the protein. This consideration is particularly important for RNA-binding proteins like IGF2BP2 that undergo conformational changes when interacting with their targets .

RNA-bound versus free states: IGF2BP2 undergoes significant conformational changes when binding to RNA targets, particularly when binding to m6A-modified RNAs. Antibodies targeting epitopes at or near RNA-binding domains may show differential binding depending on whether IGF2BP2 is RNA-bound or free, potentially leading to underestimation of protein levels in certain contexts .

To address these challenges, researchers should:

• Select antibodies with epitopes appropriate for their intended application

• Consider using multiple antibodies recognizing different epitopes for critical experiments

• Validate antibody performance in conditions mimicking their experimental setup

• Be aware that observed differences in signal might reflect changes in epitope accessibility rather than actual protein levels

Understanding these nuances allows researchers to select the appropriate antibody for specific experimental questions and accurately interpret results in the context of IGF2BP2's dynamic conformational states.

How can researchers design experiments to investigate the role of IMP-2 in m6A-modified RNA binding using specific antibodies?

To investigate IGF2BP2's role in m6A-modified RNA binding, researchers can implement the following experimental design strategies:

Methodological Approach:

• RNA Immunoprecipitation (RIP) with m6A discrimination:

  • Perform parallel RIP experiments using IGF2BP2/IMP-2 antibody on wild-type cells and cells with METTL3/METTL14 knockdown (key m6A writers).

  • Extract RNAs from both immunoprecipitates and compare binding profiles using RNA-seq.

  • Differences in binding profiles would indicate m6A-dependent RNA interactions .

• Photo-crosslinking immunoprecipitation (CLIP) with m6A site mapping:

  • Implement CLIP-seq using IMP-2 antibody to identify direct binding sites.

  • Correlate CLIP peaks with known m6A sites (from m6A-seq data).

  • Mutate identified m6A sites and measure changes in IGF2BP2 binding using luciferase reporter assays .

• In vitro binding assays with synthetic RNAs:

  • Synthesize paired RNA oligonucleotides containing identical sequences with or without m6A modifications.

  • Perform electrophoretic mobility shift assays (EMSAs) with recombinant IGF2BP2 protein.

  • Quantify binding affinity differences between modified and unmodified RNAs .

• Proximity ligation assays:

  • Use dual-antibody approach with IGF2BP2 antibody and antibodies recognizing m6A reader proteins.

  • Positive signals would indicate co-localization on the same RNA molecules.

Controls and Validation:

• Include IGF2BP2 knockout/knockdown controls in all experiments

• Validate m6A sites using m6A-specific antibodies and techniques like miCLIP

• Compare binding patterns with other m6A readers like YTHDFs as reference points

This comprehensive experimental approach would elucidate the specificity, affinity, and functional consequences of IGF2BP2 interactions with m6A-modified transcripts, providing insights into this critical RNA regulatory mechanism.

What are the most effective approaches for troubleshooting weak or inconsistent signals when using IMP-2 antibody in western blotting?

When encountering weak or inconsistent signals with IGF2BP2/IMP-2 antibody in western blotting, researchers should systematically address potential issues through this methodological troubleshooting framework:

Sample Preparation Issues:

• Protein degradation: Use fresher samples and strengthen protease inhibitor cocktail during extraction.

• Insufficient protein: Increase loading amount (30-50 μg per lane) and verify concentration using multiple measurement methods.

• Inefficient lysis: Switch to stronger lysis buffers (RIPA or SDS-based) for complete extraction of nuclear-associated proteins.

Technical Optimization:

• Transfer efficiency: For high-molecular-weight proteins like IGF2BP2, extend transfer time or decrease voltage for better transfer efficiency. Consider using PVDF membranes instead of nitrocellulose.

• Antibody concentration: Test serial dilutions (1:500, 1:1000, 1:2000) to identify optimal antibody concentration.

• Incubation conditions: Extend primary antibody incubation to overnight at 4°C and increase secondary antibody incubation to 2 hours at room temperature.

• Signal enhancement: Utilize more sensitive detection reagents like enhanced chemiluminescence (ECL) Plus or femto-sensitivity substrates.

Antibody-Specific Considerations:

• Epitope accessibility: Try different sample preparation methods if the epitope might be masked by protein folding or post-translational modifications.

• Antibody batch variation: Test antibody performance with proven positive control samples.

• Alternative antibody: Use a different IGF2BP2 antibody targeting a different epitope to confirm results.

Experimental Controls:

• Positive control: Include lysate from cell lines known to express high levels of IGF2BP2 (e.g., certain cancer cell lines).

• Loading control: Verify equal loading with antibodies against housekeeping proteins (GAPDH, β-actin).

• Recombinant protein: Include purified IGF2BP2 protein as a definitive positive control.

This systematic approach allows researchers to methodically eliminate potential sources of weak or inconsistent signals, ultimately leading to robust and reproducible western blotting results with IGF2BP2/IMP-2 antibody.

How can researchers design antibody specificity profiles to distinguish between highly similar epitopes in the IMP family?

Designing antibody specificity profiles to distinguish between highly similar epitopes in the IMP family requires sophisticated approaches that leverage both experimental and computational methods:

Computational Design Strategies:

• Epitope mapping and analysis: Perform detailed sequence alignment of IGF2BP1, IGF2BP2, and IGF2BP3 to identify regions with maximum divergence while maintaining immunogenicity. Focus on non-conserved regions, particularly those in surface-exposed loops .

• Structure-guided epitope selection: Utilize available crystal structures or predicted protein models to identify spatially distinct epitopes unique to each IMP family member, even when primary sequences show similarity .

• Binding mode identification: Employ computational models to predict different binding modes associated with each IMP family member, allowing for the design of antibodies that exploit subtle conformational differences .

Experimental Implementation:

• Phage display with negative selection: Implement phage display protocols that include rounds of negative selection against related IMP family members to remove cross-reactive antibodies, thereby enriching for IGF2BP2-specific binders .

• High-throughput screening cascades: Design screening workflows that first identify antibodies binding to IGF2BP2, then counter-screen against IGF2BP1 and IGF2BP3 to eliminate cross-reactive candidates .

• Deep mutational scanning: Generate variant libraries of potential epitopes with systematic mutations and assess binding patterns to identify critical residues for specificity .

Validation and Refinement:

• Cross-reactivity profiling: Test candidate antibodies against recombinant proteins of all IMP family members under identical conditions.

• Cell-based validation: Evaluate antibody performance in cells with selective knockdown or overexpression of each IMP family member.

• Affinity maturation: Further refine promising candidates through affinity maturation techniques that enhance specificity while maintaining or improving binding strength .

This integrated approach has been successfully demonstrated in designing antibodies with customized specificity profiles, enabling discrimination between chemically similar ligands that could not be experimentally dissociated during selection . The methodology combines empirical data from phage display experiments with computational modeling to disentangle binding modes associated with particular targets, resulting in antibodies with either highly specific binding to a single target or controlled cross-specificity across multiple targets as required by the experimental objectives .

What methodological considerations should researchers apply when interpreting antibody-based detection results in the context of IGF2BP2's multiple biological functions?

When interpreting antibody-based detection results for IGF2BP2, researchers must consider several methodological factors that affect data interpretation:

Context-Dependent Protein Interactions:
IGF2BP2 functions through interactions with various RNA targets and protein partners in different cellular contexts. Therefore, signal intensity variations across tissues or experimental conditions may reflect not only changes in protein abundance but also alterations in complex formation that affect epitope accessibility. Researchers should complement antibody-based detection with functional assays that specifically probe the biological activity of interest .

Subcellular Localization Dynamics:
IGF2BP2 shuttles between different cellular compartments depending on its functional state. In interpreting immunofluorescence or fractionation experiments, researchers must consider that apparent changes in localization patterns might represent functional shifts rather than expression changes. Counterstaining with markers for specific cellular compartments provides essential context for interpreting localization data .

Isoform-Specific Expression:
IGF2BP2 exists in multiple isoforms with potentially distinct functions. The specific epitope recognized by the antibody determines which isoforms are detected. When interpreting expression data, researchers should determine which isoforms are relevant to their biological question and select antibodies that can appropriately distinguish them, or use complementary techniques like RT-PCR to verify isoform-specific expression patterns .

Post-Translational Modifications:
Modifications like phosphorylation can alter IGF2BP2 function and potentially affect antibody binding. When studying IGF2BP2 in signaling contexts, researchers should consider using phospho-specific antibodies or complementary approaches like mass spectrometry to accurately interpret functional states.

By applying these methodological considerations, researchers can move beyond simplistic presence/absence interpretations to develop nuanced understanding of IGF2BP2's diverse biological functions in different experimental contexts.

How should researchers approach data analysis when using IMP-2 antibody in conjunction with other detection methods?

Methodological Integration Framework:

• Data normalization and standardization:

  • Establish appropriate normalization controls for each detection method

  • For antibody-based methods, normalize to loading controls (e.g., GAPDH, β-actin)

  • For transcript analysis, use established reference genes

  • Create standardized scales to allow meaningful cross-method comparisons

• Correlation analysis approach:

  • Perform quantitative correlation analysis between protein levels (detected by IMP-2 antibody) and mRNA levels (from qRT-PCR or RNA-seq)

  • Calculate Pearson or Spearman correlation coefficients to assess relationship strength

  • Analyze discrepancies as potential indicators of post-transcriptional regulation

• Multi-method validation strategy:

  • Implement triangulation of results across methods with different underlying principles

  • When methods disagree, systematically investigate potential causes rather than simply discarding outlier results

  • Weight evidence based on each method's established reliability for the specific application

• Statistical considerations:

  • Apply appropriate statistical tests based on data distribution and experimental design

  • Use multiple comparison corrections when analyzing data across many conditions or samples

  • Implement power analysis to ensure sufficient sample sizes for each method

Example Analysis Workflow:

When investigating IGF2BP2's role in regulating a specific target mRNA:

• Quantify IGF2BP2 protein levels via western blot using IMP-2 antibody

• Measure target mRNA expression using qRT-PCR

• Assess protein-RNA interaction using RIP with IMP-2 antibody

• Validate functional impact through reporter assays

• Integrate all data points to develop a comprehensive model of regulation

This methodological approach acknowledges the complementary nature of different detection methods and leverages their combined strengths to overcome the limitations inherent to any single technique.

What are the best practices for interpreting antibody validation data when selecting an IMP-2 antibody for specialized research applications?

When selecting an IGF2BP2/IMP-2 antibody for specialized research applications, researchers should implement these best practices for interpreting validation data:

Comprehensive Validation Assessment Framework:

Critical Interpretation Steps:

• Application-specific evaluation:
  Different applications place distinct demands on antibodies. For IP applications, assess data showing pull-down efficiency and specificity. For immunofluorescence, examine subcellular localization patterns in known positive controls. An antibody performing well in western blotting may not necessarily perform optimally in other applications .

• Sample context consideration:
  Evaluate validation data in cellular/tissue contexts most relevant to your research. Antibody performance can vary significantly across sample types due to differences in protein abundance, post-translational modifications, and interfering factors.

• Validation data hierarchy:
  Prioritize validation data from knockout/knockdown systems over other methods. Next, consider peptide competition data, followed by concordance with orthogonal detection methods.

• Literature assessment:
  When reviewing publications using the antibody, evaluate the rigor of their validation rather than merely counting citations. One thoroughly validated application provides stronger evidence than multiple publications with limited validation.

• Vendor data limitations:
  Recognize that vendor-provided data typically presents optimal results. Request additional information about experimental conditions and consider performing scaled-down validation in your specific research context before committing to large experiments.

By applying these interpretation principles to antibody validation data, researchers can select IGF2BP2/IMP-2 antibodies most likely to yield reliable results in their specific research applications, ultimately enhancing data quality and reproducibility .